Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SKI2162
- Development stage
- Preclinical
- Lead developer
- SK Chemicals
- Modality
- Small Molecules
01
Overview
SKI2162: sourced facts only. name: "SKI2162, a small-molecule inhibitor of the TGF-β type I receptor (ALK5)" target: "SKI2162, a small-molecule inhibitor of the TGF-β type I receptor (ALK5)" developer: "Life Science Research Center, SK Chemicals, Seongnam-si, Korea." stage: "In RIF a mouse model, SKI2162 reduced late skin reactions and leg-contracture without jeopardizing the acute skin reaction." modality: "SKI2162, a small-molecule inhibitor of the TGF-β type I receptor (ALK5)"
02
Targets
Beyond the preview
Go deeper on SKI2162.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SKI2162.